D. Boral Capital Rates Anixa Biosciences (ANIX) buy

Anixa Biosciences receives a new 'buy' rating and a $10 price target from D. Boral Capital, a 257.14% upside from the current price.

By TradeTexts Research Desk · Published Jun 30, 2026, 9:05 PM EDT · Updated Jul 1, 2026, 3:01 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

D. Boral Capital rated Anixa Biosciences, Inc. ($ANIX) "buy" with a $10 price target on June 30, 2026.

Since the rating, $ANIX is up 5.7% after 1 week, up 27.1% after 1 month and down 4.6% to date (from the $2.80 close on Jun 30, 2026).

ANIX Anixa Biosciences, Inc.

$2.67 -15.51% year to date

Daily close · Oct 16, 2026

Key Points

D. Boral Capital raised its price target on Anixa Biosciences to $10 on June 30, 2026, while maintaining a 'buy' rating.
D. Boral Capital's $10 price target implies 257.14% upside from Anixa Biosciences, Inc.'s ($ANIX) current $2.80 share price.
Shares of NasdaqCM:ANIX traded near $2.85 on Wednesday, with a market cap of about $94.9 million.
Vanguard Capital Management opened a new position in Anixa Biosciences with 1,314,982 shares valued at around $3.39 million.

Get $ANIX trade alerts by text

We text you when insiders, Congress or big funds trade $ANIX. Free.

Not investment advice. TradeTexts is not a registered investment adviser, and this automated Anixa Biosciences, Inc. alert may contain errors. Disclosures

D. Boral Capital has raised its price target for Anixa Biosciences, Inc. (NasdaqCM:ANIX) to $10 while maintaining a 'buy' rating. This update came on June 30, 2026, from analyst Jason Kolbert.

Analyst rating track record

D. Boral Capital vs. the S&P 500

YTD return -19.94% hypothetical

All-time return -82.62% S&P 500 +27.98%

vs. S&P 500 -110.60% behind the index

Hypothetical returns from D. Boral Capital's disclosed trades, not real profit or advice. How we model this.

Anixa Biosciences, Inc. Stock Up 1.1%

Shares of Anixa Biosciences, Inc. traded near $2.85 on Wednesday. The company, which is listed on the NasdaqCM, has a market cap of approximately $94.9 million. Anixa is not currently profitable, with a forward P/E ratio of -9.0. The stock has seen a 52-week low of $2.32 and a high of $5.46, with a 50-day moving average of $2.79 and a 200-day moving average of $3.30. The company maintains a strong liquidity position with a current ratio of 9.788 and a quick ratio of 9.155.

12-month forecast

$ANIX price target

Anixa Biosciences, Inc. daily closes and this analyst's $10 target. Not advice.

Insider Buying and Selling at Anixa Biosciences, Inc.

Recent insider activity at Anixa Biosciences includes several purchases. On June 16, 2026, Titterton Lewis Jr bought 2,836 shares at an average price of $2.64 per share. Earlier, on June 12, 2026, CEO Amit Kumar acquired 21,000 shares at $2.50 each. In January, Arnold Baskies made multiple purchases, including 10,000 shares at $3.04 each, and earlier in the year, he bought 25,000 shares.

Analysts Set New Price Targets

On June 30, 2026, D. Boral Capital assumed coverage on Anixa Biosciences with a 'buy' rating and a $10 price target. This aligns with the consensus target mean price of $10, supported by three analyst opinions.

Other Institutional Activity in Anixa Biosciences

Vanguard Capital Management LLC recently opened a new position in Anixa Biosciences, acquiring 1,314,982 shares valued at around $3.39 million. Meanwhile, UBS Group AG increased its holdings by 92,564 shares, resulting in a total of 551,637 shares worth approximately $1.42 million, marking a 20.2% increase. Geode Capital Management, LLC also added 13,816 shares, bringing its total to 364,731 shares valued at $941,440.

About Anixa Biosciences

Anixa Biosciences, Inc. is a biotechnology company based in San Jose, California. It focuses on developing therapies and vaccines targeting unmet needs in oncology, including a chimeric endocrine receptor-T cell therapy for ovarian cancer and a breast cancer vaccine. Led by CEO Dr. Amit Kumar, the company aims to address various intractable cancers through its innovative vaccine technologies.

Bottom Line

D. Boral Capital's recent rating and price target increase for Anixa Biosciences highlights continued interest in the company's potential. With a focus on innovative cancer therapies and vaccines, Anixa remains a company to watch. As always, it's important to remember that these ratings are based on past and current data, and future performance can vary.